Research ExplorerPublicationsEfficacy and quality of life for FOLFOX/bevacizumab +/- irin...

Efficacy and quality of life for FOLFOX/bevacizumab +/- irinotecan in first-line metastatic colorectal cancer-final results of the AIO CHARTA trial

Standard

Efficacy and quality of life for FOLFOX/bevacizumab +/- irinotecan in first-line metastatic colorectal cancer-final results of the AIO CHARTA trial. / Schmoll, Hans-Joachim; Mann, Julia; Meinert, Fabian; Garlipp, Benjamin; Borchert, Kersten; Vogel, Arndt; Goekkurt, Eray; Kaiser, Ulrich; Hoeffkes, Heinz-Gert; Rüssel, Jörn; Kanzler, Stephan; Edelmann, Thomas; Forstbauer, Helmut; Göhler, Thomas; Hannig, Carla; Hildebrandt, Bert; Roll, Carsten; Bokemeyer, Carsten; Steighardt, Jörg; Cygon, Franziska; Ibach, Stefan; Stein, Alexander; Tintelnot, Joseph.

In: BRIT J CANCER, Vol. 130, No. 2, 02.2024, p. 233-241.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Schmoll, H-J, Mann, J, Meinert, F, Garlipp, B, Borchert, K, Vogel, A, Goekkurt, E, Kaiser, U, Hoeffkes, H-G, Rüssel, J, Kanzler, S, Edelmann, T, Forstbauer, H, Göhler, T, Hannig, C, Hildebrandt, B, Roll, C, Bokemeyer, C, Steighardt, J, Cygon, F, Ibach, S, Stein, A & Tintelnot, J 2024, 'Efficacy and quality of life for FOLFOX/bevacizumab +/- irinotecan in first-line metastatic colorectal cancer-final results of the AIO CHARTA trial', BRIT J CANCER, vol. 130, no. 2, pp. 233-241. https://doi.org/10.1038/s41416-023-02496-4

APA

Schmoll, H-J., Mann, J., Meinert, F., Garlipp, B., Borchert, K., Vogel, A., Goekkurt, E., Kaiser, U., Hoeffkes, H-G., Rüssel, J., Kanzler, S., Edelmann, T., Forstbauer, H., Göhler, T., Hannig, C., Hildebrandt, B., Roll, C., Bokemeyer, C., Steighardt, J., ... Tintelnot, J. (2024). Efficacy and quality of life for FOLFOX/bevacizumab +/- irinotecan in first-line metastatic colorectal cancer-final results of the AIO CHARTA trial. BRIT J CANCER, 130(2), 233-241. https://doi.org/10.1038/s41416-023-02496-4

Vancouver

Schmoll H-J, Mann J, Meinert F, Garlipp B, Borchert K, Vogel A et al. Efficacy and quality of life for FOLFOX/bevacizumab +/- irinotecan in first-line metastatic colorectal cancer-final results of the AIO CHARTA trial. BRIT J CANCER. 2024 Feb;130(2):233-241. https://doi.org/10.1038/s41416-023-02496-4

Bibtex

@article{e56a5c65d19a461ebe4c2482230e3552,
title = "Efficacy and quality of life for FOLFOX/bevacizumab +/- irinotecan in first-line metastatic colorectal cancer-final results of the AIO CHARTA trial",
abstract = "BACKGROUND: FOLFOXIRI plus bevacizumab has demonstrated benefits for metastatic colorectal cancer (mCRC) patients. However, challenges arise in its clinical implementation due to expected side effects and a lack of stratification criteria.METHODS: The AIO {"}CHARTA{"} trial randomised mCRC patients into clinical Group 1 (potentially resectable), 2 (unresectable/risk of rapid progression), or 3 (asymptomatic). They received FOLFOX/bevacizumab +/- irinotecan. The primary endpoint was the 9-month progression-free survival rate (PFSR@9). Secondary endpoints included efficacy in stratified groups, QoL, PFS, OS, ORR, secondary resection rate, and toxicity.RESULTS: The addition of irinotecan to FOLFOX/bevacizumab increased PFSR@9 from 56 to 67%, meeting the primary endpoint. The objective response rate was 61% vs. 69% (P = 0.21) and median PFS was 10.3 vs. 12 months (HR 0.83; P = 0.17). The PFS was (11.4 vs. 12.9 months; HR 0.83; P = 0.46) in potentially resectable patients, with a secondary resection rate of 37% vs. 51%. Moreover, Group 3 (asymptomatic) patients had a PFS of 11.1 vs. 16.1 months (HR 0.6; P = 0.14). The addition of irinotecan did not diminish QoL.CONCLUSION: The CHARTA trial, along with other studies, confirms the efficacy and tolerability of FOLFOXIRI/bevacizumab as a first-line treatment for mCRC. Importantly, clinical stratification may lead to its implementation.TRIAL REGISTRATION: The trial was registered as NCT01321957.",
author = "Hans-Joachim Schmoll and Julia Mann and Fabian Meinert and Benjamin Garlipp and Kersten Borchert and Arndt Vogel and Eray Goekkurt and Ulrich Kaiser and Heinz-Gert Hoeffkes and J{\"o}rn R{\"u}ssel and Stephan Kanzler and Thomas Edelmann and Helmut Forstbauer and Thomas G{\"o}hler and Carla Hannig and Bert Hildebrandt and Carsten Roll and Carsten Bokemeyer and J{\"o}rg Steighardt and Franziska Cygon and Stefan Ibach and Alexander Stein and Joseph Tintelnot",
note = "{\textcopyright} 2023. The Author(s).",
year = "2024",
month = feb,
doi = "10.1038/s41416-023-02496-4",
language = "English",
volume = "130",
pages = "233--241",
journal = "BRIT J CANCER",
issn = "0007-0920",
publisher = "NATURE PUBLISHING GROUP",
number = "2",

}

RIS

TY - JOUR

T1 - Efficacy and quality of life for FOLFOX/bevacizumab +/- irinotecan in first-line metastatic colorectal cancer-final results of the AIO CHARTA trial

AU - Schmoll, Hans-Joachim

AU - Mann, Julia

AU - Meinert, Fabian

AU - Garlipp, Benjamin

AU - Borchert, Kersten

AU - Vogel, Arndt

AU - Goekkurt, Eray

AU - Kaiser, Ulrich

AU - Hoeffkes, Heinz-Gert

AU - Rüssel, Jörn

AU - Kanzler, Stephan

AU - Edelmann, Thomas

AU - Forstbauer, Helmut

AU - Göhler, Thomas

AU - Hannig, Carla

AU - Hildebrandt, Bert

AU - Roll, Carsten

AU - Bokemeyer, Carsten

AU - Steighardt, Jörg

AU - Cygon, Franziska

AU - Ibach, Stefan

AU - Stein, Alexander

AU - Tintelnot, Joseph

N1 - © 2023. The Author(s).

PY - 2024/2

Y1 - 2024/2

N2 - BACKGROUND: FOLFOXIRI plus bevacizumab has demonstrated benefits for metastatic colorectal cancer (mCRC) patients. However, challenges arise in its clinical implementation due to expected side effects and a lack of stratification criteria.METHODS: The AIO "CHARTA" trial randomised mCRC patients into clinical Group 1 (potentially resectable), 2 (unresectable/risk of rapid progression), or 3 (asymptomatic). They received FOLFOX/bevacizumab +/- irinotecan. The primary endpoint was the 9-month progression-free survival rate (PFSR@9). Secondary endpoints included efficacy in stratified groups, QoL, PFS, OS, ORR, secondary resection rate, and toxicity.RESULTS: The addition of irinotecan to FOLFOX/bevacizumab increased PFSR@9 from 56 to 67%, meeting the primary endpoint. The objective response rate was 61% vs. 69% (P = 0.21) and median PFS was 10.3 vs. 12 months (HR 0.83; P = 0.17). The PFS was (11.4 vs. 12.9 months; HR 0.83; P = 0.46) in potentially resectable patients, with a secondary resection rate of 37% vs. 51%. Moreover, Group 3 (asymptomatic) patients had a PFS of 11.1 vs. 16.1 months (HR 0.6; P = 0.14). The addition of irinotecan did not diminish QoL.CONCLUSION: The CHARTA trial, along with other studies, confirms the efficacy and tolerability of FOLFOXIRI/bevacizumab as a first-line treatment for mCRC. Importantly, clinical stratification may lead to its implementation.TRIAL REGISTRATION: The trial was registered as NCT01321957.

AB - BACKGROUND: FOLFOXIRI plus bevacizumab has demonstrated benefits for metastatic colorectal cancer (mCRC) patients. However, challenges arise in its clinical implementation due to expected side effects and a lack of stratification criteria.METHODS: The AIO "CHARTA" trial randomised mCRC patients into clinical Group 1 (potentially resectable), 2 (unresectable/risk of rapid progression), or 3 (asymptomatic). They received FOLFOX/bevacizumab +/- irinotecan. The primary endpoint was the 9-month progression-free survival rate (PFSR@9). Secondary endpoints included efficacy in stratified groups, QoL, PFS, OS, ORR, secondary resection rate, and toxicity.RESULTS: The addition of irinotecan to FOLFOX/bevacizumab increased PFSR@9 from 56 to 67%, meeting the primary endpoint. The objective response rate was 61% vs. 69% (P = 0.21) and median PFS was 10.3 vs. 12 months (HR 0.83; P = 0.17). The PFS was (11.4 vs. 12.9 months; HR 0.83; P = 0.46) in potentially resectable patients, with a secondary resection rate of 37% vs. 51%. Moreover, Group 3 (asymptomatic) patients had a PFS of 11.1 vs. 16.1 months (HR 0.6; P = 0.14). The addition of irinotecan did not diminish QoL.CONCLUSION: The CHARTA trial, along with other studies, confirms the efficacy and tolerability of FOLFOXIRI/bevacizumab as a first-line treatment for mCRC. Importantly, clinical stratification may lead to its implementation.TRIAL REGISTRATION: The trial was registered as NCT01321957.

U2 - 10.1038/s41416-023-02496-4

DO - 10.1038/s41416-023-02496-4

M3 - SCORING: Journal article

C2 - 37996507

VL - 130

SP - 233

EP - 241

JO - BRIT J CANCER

JF - BRIT J CANCER

SN - 0007-0920

IS - 2

ER -